Frontlight ResearchEarly access
Taking people in United StatesPhase 1
Ruxolitinib cream used on skin in people with hidradenitis suppurativa
Tests ruxolitinib cream in adults and teens with hidradenitis suppurativa.
Key facts
- Who runs it
- Incyte Corporation
- Where
- Baton Rouge, Bolivar, Bowling Green, Castle Rock, Columbus, Fargo, Fountain Valley, New York, Northridge, Oklahoma City, Orange, Philadelphia, Phoenix, Sanford, Sweetwater, Tampa, Thousand Oaks, Troy, and West Lafayette, United StatesSee the 21 sites
- Trial code
- Registry title
- Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 24 people, planned
- Started
- 3 Nov 2025
- Expected to end
- 9 Dec 2026
- Type of study
- Interventional
- Treatments tested
- Ruxolitinib Cream
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 to 75 with hidradenitis suppurativa (HS), a long-lasting skin disease with painful lumps and abscesses. Everyone uses ruxolitinib 1.5% cream on the affected skin.
- Age
- 12 Years to 75 Years
- Sex
- All sexes
- Disease stage
- HS diagnosed at least 6 months before screening, Hurley Stage I, II or III. At least 4 abscesses and inflamed lumps in at least 3 different body areas. The skin to treat must cover more than 20% of the body surface.
- Earlier treatment
- People must agree not to use antibiotic creams or antibiotic pills for HS during the treatment period.
Main reasons for not taking part
- Another skin condition, now or in the past, that could confuse the HS assessment
- Heart or blood vessel disease that is not under control, or blood clots
- Certain cancers or certain infections
- Severe anemia or very low platelet or neutrophil counts
- Lab test results outside the limits set by the protocol
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Diagnosis of HS for at least 6 months before screening visit
- Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits
- Total estimated treatment BSA > 20% at screening and baseline
- Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period
- Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol
- Further inclusion criteria apply
Who cannot take part
- Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator
- Laboratory values outside of the protocol-defined ranges
- Further exclusion criteria apply
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 75 years old?
Where in United States
- DelRicht ResearchBaton Rouge, United StatesTaking people
- Red River Research PartnersBolivar, United StatesTaking people
- Equity Medical, LLCBowling Green, United StatesTaking people
- Clarity DermatologyCastle Rock, United StatesNo longer taking part
- Lane Dermatology and Dermatologic SurgeryColumbus, United StatesTaking people
- Centricity Research ColumbusColumbus, United StatesNo longer taking part
- Red River Research PartnersFargo, United StatesTaking people
- First OC DermatologyFountain Valley, United StatesNo longer taking part
- Dr Bobby Buka, Md Greenwich VillageNew York, United StatesTaking people
- Equity Medical LLCNew York, United StatesTaking people
- Amicis Research Center ValenciaNorthridge, United StatesTaking people
- Unity Clinical ResearchOklahoma City, United StatesTaking people
- Children's Hospital of Orange CountyOrange, United StatesTaking people
- Paddington Testing Co IncPhiladelphia, United StatesNo longer taking part
- Saguaro DermatologyPhoenix, United StatesTaking people
- International Clinical Research Tennessee LlcSanford, United StatesTaking people
- LENUS Research & Medical Group, LLCSweetwater, United StatesTaking people
- TrueBlue Clinical ResearchTampa, United StatesTaking people
- Clinical Trials Research InstituteThousand Oaks, United StatesTaking people
- Revival Research Institute, Llc TroyTroy, United StatesNo longer taking part
- Options Research Group LLCWest Lafayette, United StatesTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
The group in the trial
- Ruxolitinib 1.5 % CreamTreatment being tested
Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.
Treatment: Ruxolitinib Cream
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
- Plain-language title
- Ruxolitinib cream used on skin in people with hidradenitis suppurativaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07049575, who can take part
- Record updated
- 9 October 2026